Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LYEL with free AI briefings, catalyst countdowns, and dilution alerts.

LYEL · Lyell Immunopharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$269.9M Cash on Hand
23.6mo Cash Runway
6.7% Short Interest
$37.62 Analyst Target (8)
Follow LYEL by email Get an email when LYEL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LYEL, unsubscribe in one click. Privacy

📣 What LYEL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rondecabtagene Autoleucel Large B-cell Lymphoma Phase 3 · NCT07188558 Recruiting
Fludarabine Relapsed Non-Hodgkin Lymphoma Phase 1/2 · NCT05826535 Recruiting
IMPT-514 Systemic Lupus Erythematosus Phase 1/2 · NCT06153095 Withdrawn
Autologous GCC-targeting CAR T-cells LYL273 Colorectal Cancer Phase 1/2 · NCT05319314 Recruiting
Autologous Anti-ROR1 CAR T-cells LYL797 Triple Negative Breast Cancer Phase 1 · NCT05274451 Terminated
Autologous Polyclonal Tumor Infiltrating… Melanoma Phase 1 · NCT05573035 Terminated
Immune Checkpoint Inhibitors Myocarditis N/A · NCT05349058 Unknown

Also used in these trials (approved or third-party drugs, not LYEL's own candidates): Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LYEL holds $269.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $34.2M/quarter from operations, an estimated runway of 23.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LYEL files for a raise →

👥 Who Owns LYEL

Insiders 16.7% Other 5%+ holders 34.7% Institutions (140 holders) 48.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
ARCH Venture Fund IX, L.P. 5%+ holder (13G) 5,568,424 22.65% 2026-11-04
Arch Venture Management, Llc Institution (13F) 3,247,162 13.21% 2026-09-30
Innovative Cellular Therapeutics Holding
10% owner
Insider 2,818,980 11.47% 2026-07-27
Explore Investments LLC 5%+ holder (13G) 1,529,054 6.22% 2026-03-31
GSK plc Institution (13F) 1,512,659 6.15% 2026-09-30
EULER FUND, L.P. 5%+ holder (13G) 1,426,528 5.80% 2026-03-06
ARCH Venture Partners IX, LLC
10% owner
Insider 910,317 3.70% 2026-11-04
ARCH Venture Fund XIII, L.P.
10% owner
Includes shares also reported by ARCH Venture Partners IX, LLC, counted once
Insider 910,317 3.70% 2026-11-04
Blackrock Inc. Institution (13F) 799,057 3.25% 2026-09-30
Orland Properties Ltd. Institution (13F) 754,698 3.07% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 748,848 3.05% 2026-09-30
Decheng Capital LLC Institution (13F) 692,050 2.81% 2026-09-30

Share count 24,585,565 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-12
Seely Lynn
Sale (S) 545 $15.93 63,354
2026-11-10
filed 2026-11-12
Hill Stephen J.
Sale (S) 88 $15.93 16,728
2026-11-10
filed 2026-11-12
Lee Gary K.
Sale (S) 129 $15.93 16,091
2026-11-10
filed 2026-11-12
Bulis Veronica Sanchez
Sale (S) 416 $15.93 14,383
2026-11-04
filed 2026-11-05
ARCH Venture Fund XIII, L.P.
Purchase (P) 2,321,262 $10.77 3,747,790

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full LYEL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LYEL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.